What the $46m Veloxis Pharmaceuticals settlement means for Envarsus XR
Veloxis Pharmaceuticals will pay over $46 million over Envarsus XR conduct. See why five years of compliance oversight could matter even more.
Pharma & Biotech
Pharma & Biotech
Veloxis Pharmaceuticals’ pegrizeprument gets orphan status—will FDA incentives accelerate clinical momentum?
Veloxis earns FDA orphan status for pegrizeprument in liver transplant rejection. Find out what this means for the future of immunosuppressive therapy.